AlphaGen
Access AlphaGen
Company Narratives

Citi Pharma Q3 FY26: Margins Strengthen as Sales Ease, but Cash Conversion Weakens

Citi Pharma lifted Q3 profit despite lower sales as gross margins improved, but receivables, inventory and borrowings kept cash conversion under pressure.

Sep 20, 2026

Verdict

Citi Pharma’s March 2026 quarter was stronger than the top line suggests. Company-level, unaudited Q3 sales fell 7.7% year on year to Rs3.08 billion, yet gross profit rose 6.9%, profit before tax rose 11.0%, and profit after tax increased 25.0% to Rs275.4 million. The central change was margin expansion: cost of sales declined faster than revenue, allowing gross margin to improve by about 232 basis points to 16.9%. Across the first nine months of FY26, the improvement was even clearer, with sales up 6.8%, gross profit up 37.3% and profit after tax up 30.1%. Management attributes the cumulative margin improvement to tighter cost control, better product mix, a higher contribution from formulations and production efficiencies.

The earnings quality is reasonably strong because the improvement did not depend on a large non-operating gain: nine-month other income fell by more than half while operating profit rose 40.9%. The main weakness is cash conversion. Working capital absorbed nearly Rs2.0 billion in nine months, net operating cash flow remained negative at Rs972.8 million, short-term borrowings increased, and the cash-equivalent balance fell sharply. The next result therefore needs to show whether the margin gains can be converted into cash without further balance-sheet funding.

Results at a glance

  • Company Name: Citi Pharma Ltd
  • Ticker: CPHL
  • Reporting period: Nine months and third quarter ended March 31, 2026
  • Reporting basis: Company-level unaudited condensed interim financial statements prepared under IAS 34. The official filing is not presented as consolidated group accounts.
  • 9MFY26 sales: Rs10.79 billion, up 6.8% year on year. Gross profit: Rs2.00 billion, up 37.3%. Operating profit: Rs1.65 billion, up 40.9%.
  • 9MFY26 profit after tax: Rs883.4 million, up 30.1%, with EPS of Rs3.87 versus Rs2.97.
  • Q3 FY26 sales: Rs3.08 billion, down 7.7%. Gross margin improved to 16.9% from 14.6%, while PAT rose to Rs275.4 million from Rs220.4 million.
  • The Board announced no cash dividend, bonus issue, rights issue or other entitlement with the March-quarter result.

AlphaGen model outputs — these are AlphaGen model outputs, not company-reported figures.

  • Alpha QoQ Score: 43.95
  • TTM Performance Score: 95.66
  • 3Y Business Perf Score: 97.07
  • Sector Leadership Score: 44.3176

What improved

Margin expansion was the defining improvement. Nine-month gross margin increased to 18.5% from 14.4%, an expansion of about 411 basis points. Operating margin rose to 15.3% from 11.6%. The effect remained visible in Q3 despite weaker revenue: gross margin improved to 16.9% from 14.6%, and operating margin to 13.2% from 11.8%. That means the company generated more gross and operating profit from a smaller quarterly revenue base.

Management’s explanation is economically coherent with the accounts. The directors attribute the nine-month gross-profit improvement to tighter cost controls, an improved product portfolio mix, a higher sales contribution from formulation products and better production efficiency. The financial statements support the outcome: nine-month sales rose Rs687 million, but gross profit increased by roughly Rs543 million because cost of sales rose only 1.7%. In Q3, cost of sales fell 10.2% against a 7.7% decline in sales, which protected gross profit.

The quality of the nine-month operating improvement is also notable. Other income fell 52.1% to Rs79.3 million, mainly because profit on term deposits declined and the prior period included realized gains on shares. Yet operating profit increased by about Rs480 million. The earnings step-up was therefore generated primarily above the non-operating-income line rather than by investment gains or treasury income.

Q3 financing pressure also eased. Finance cost fell 19.2% year on year to Rs80.0 million in the quarter, helping profit before tax increase despite the revenue decline. That quarterly relief should not be generalized to the full nine months, however: cumulative finance cost increased 21.8% to Rs282.0 million, consistent with the company carrying a larger short-term borrowing balance through the period.

What weakened / needs attention

The most visible weakness is the Q3 revenue contraction. Sales fell by about Rs256 million from the comparable quarter even though the nine-month top line remained positive. The filing does not disclose Q3 unit volumes or a detailed product-by-product revenue bridge, so the decline cannot be responsibly split between volume, pricing and mix. It is therefore safer to describe the quarter as margin-led earnings growth rather than a broad-based revenue expansion.

Selling expenses rose sharply. Nine-month selling expense increased 49.1% to Rs178.4 million, while Q3 selling expense increased 68.8% to Rs60.6 million. The report does not provide a detailed explanation for that increase. For now, gross-margin expansion more than absorbed the higher commercial cost, but the next cycle should show whether the spending is supporting sustainable formulation growth or simply creating a higher operating cost burden.

The Q3 tax line also amplified bottom-line growth. Profit before tax increased about 11%, but the quarterly income-tax charge fell about 31%, allowing PAT to rise 25%. The nine-month tax charge, by contrast, increased to Rs469.0 million and the cumulative effective tax rate stayed broadly around one-third of pre-tax profit. The lower Q3 tax charge therefore should not be treated as a new recurring earnings driver without further disclosure.

Cash flow: stronger accounting profit, weaker conversion

Cash conversion is the central tension in the result. Before working-capital movements, operating cash generation improved 28.9% to Rs1.87 billion. Working capital then absorbed Rs2.00 billion, compared with Rs1.30 billion a year earlier. After finance charges, taxes and worker-related payments, net cash used in operating activities widened to Rs972.8 million from Rs602.5 million.

The composition matters. Trade receivables absorbed Rs1.14 billion and inventory another Rs476.9 million. Those outflows were actually smaller than the comparable-period absorptions, but trade and other payables reversed from an Rs888.6 million source of cash last year to a Rs286.8 million use of cash this year. Advances and prepayments also used cash. The company therefore improved profit before working capital, but did not convert that improvement into operating cash.

The balance sheet confirms the build. Between June 2025 and March 2026, inventory increased 12.1% to Rs4.41 billion and trade debts increased 37.0% to Rs4.22 billion. Short-term borrowings rose 19.4% to Rs3.42 billion. Current assets of Rs9.97 billion still exceeded current liabilities of Rs7.63 billion, leaving the current ratio around 1.31x, but the liquidity cushion increasingly consisted of inventory and receivables rather than cash.

Cash and bank balances ended March at Rs321.1 million, down from Rs603.6 million at June 2025, while short-term investments fell from Rs956.4 million to only Rs3.1 million. On the cash-flow statement, cash equivalents fell by about Rs1.17 billion during the nine months. The company funded part of the gap with Rs556.5 million of additional short-term borrowing while also paying about Rs801.2 million of dividends relating to the prior year.

Industry context: company margins improved against a difficult production backdrop

Pakistan’s broader manufacturing backdrop was improving, with PBS reporting overall large-scale manufacturing growth of 6.48% in July–March FY26. Pharmaceuticals were an exception: the Pakistan Economic Survey reports a 5.1% contraction in pharmaceutical-sector output over the same period, compared with growth in the prior year, with weakness in liquids/syrups, injections and capsules while some categories such as ointments and tablets grew.

Citi Pharma’s 6.8% nine-month revenue growth and much stronger gross-profit growth therefore occurred while the official production index for the sector was contracting. Revenue value and the LSM production index are not directly comparable, so this is not proof of market-share gain. It does, however, make management’s product-mix and efficiency explanation more relevant: the company improved earnings without relying on an industry-wide volume boom.

Peer evidence also suggests that margin improvement was not unique to Citi Pharma. GlaxoSmithKline Pakistan reported March-quarter sales and profit growth, while Highnoon Laboratories also posted higher revenue and profit. Product portfolios, business scale and fiscal calendars differ, so these are directional checks rather than like-for-like benchmarks. The useful conclusion is that the sector was mixed: official production output was down, yet several listed manufacturers still expanded earnings through pricing, mix and cost dynamics.

Input conditions remained uncertain. Citi Pharma’s directors specifically flagged API prices, freight, logistics, import costs and supply-chain lead times as risks. SBP’s March 9 monetary-policy statement independently noted that the Middle East conflict had sharply increased global fuel prices as well as freight and insurance costs. Against that backdrop, Citi Pharma’s margin expansion is meaningful, but it also raises the bar for sustaining efficiency if input inflation persists.

Recurring versus non-recurring earnings drivers

  • Potentially recurring: better product mix, a larger formulation contribution, tighter cost control and production efficiency are operating drivers that can persist if execution and demand remain supportive.
  • Potentially recurring but funding-sensitive: finance cost can improve if borrowing needs fall, but current nine-month finance cost was still higher and short-term borrowings increased, so working-capital discipline is essential.
  • Non-operating income was not the growth engine: nine-month other income fell from Rs165.8 million to Rs79.3 million. This makes the operating-profit increase more representative of core business improvement.
  • Quarter-specific tax benefit: the lower Q3 tax charge helped PAT grow much faster than PBT. With the nine-month tax burden still substantial, that quarterly tax effect should not be extrapolated.
  • Balance-sheet revaluation is separate from current earnings: the Rs5.38 billion land revaluation surplus was already present at the July 1, 2025 opening balance and did not increase during the reported nine months. FY26 comprehensive income for the period equals reported profit, so the large year-on-year equity step-up is not a March-quarter earnings event.

What changed versus the historical pattern

Citi Pharma had already been improving margins before FY26. PSX annual data show FY2025 gross margin at 15.34%, up from 12.78% in FY2024. The 9MFY26 gross margin of 18.53% represents another step higher. At the bottom line, the company earned Rs883.4 million in the first nine months of FY26, already roughly 99% of the Rs892.0 million reported for the entire FY2025. This shows that the current improvement is not simply a recovery from a loss-making base; it is an acceleration in profitability relative to an already profitable prior year.

The caution is that Q3 itself broke the nine-month top-line trend. Revenue declined while margins expanded. That can still be a healthy outcome if the company is intentionally shifting toward higher-value formulations or stronger-margin products, but the report does not disclose enough product-level volume and pricing data to prove that the Q3 sales decline was strategic. Future results need to show whether revenue growth resumes without giving back the margin gains.

Projects and operating developments

Management says it is prioritizing completion and operationalization of biotech formulation capacity, a penicillin project, veterinary formulations through a wholly owned subsidiary, and export readiness. The veterinary subsidiary had already commenced operations through outsourced third-party manufacturing while the company worked toward a dedicated plant. These initiatives are strategically relevant because they can change product mix and address new markets, but the March filing does not quantify their current contribution to Citi Pharma’s reported revenue or profit.

The notes also show that Rs922.6 million of previously unutilized IPO proceeds, originally earmarked for a hospital facility, had been reallocated following the June 2025 EOGM toward biotech, carbapenem and penicillin formulation projects. These projects should be monitored as capital-deployment milestones rather than treated as earnings already delivered.

What to monitor next

  • Revenue recovery: whether the Q3 sales decline reverses while gross margin remains near the improved FY26 level.
  • Receivables and inventory: trade debts of Rs4.22 billion and inventory of Rs4.41 billion are now the key balance-sheet variables for cash conversion.
  • Operating cash flow: stronger profit before working-capital movements needs to translate into positive cash generation rather than further borrowing.
  • Short-term borrowing and finance cost: the quarter showed lower finance cost, but nine-month finance cost and closing short-term debt were both higher.
  • Formulation mix: management links margin improvement to higher formulation contribution. Product-level disclosure or sustained margin performance would help validate that as a durable structural change.
  • Biotech, penicillin and veterinary projects: watch commissioning, own-plant progress, regulatory approvals, utilization and whether these investments begin contributing measurable sales and cash flow.
  • Input-cost environment: API prices, freight, FX and supply-chain disruptions remain important because the current earnings improvement depends on protecting the stronger gross margin.

Sources

Explore more research

All articles